Charles River Laboratories International, Inc. (CRL) Presents at Evercore 8th Annual Healthcare Conference Transcript
Charles River Laboratories International, Inc. ( CRL ) Jefferies London Healthcare Conference 2025 November 18, 2025 6:30 AM EST Company Participants Birgit Girshick - Corporate Executive VP & COO Conference Call Participants David Windley - Jefferies LLC, Research Division Presentation David Windley Jefferies LLC, Research Division All right. Good morning, everybody.
Explore how Charles River's (CRL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
| - Industry | - Sector | James C. Foster CEO | XFRA Exchange | US1598641074 ISIN |
| US Country | 18,700 Employees | - Last Dividend | - Last Split | - IPO Date |
Charles River Laboratories International, Inc. stands as a pivotal organization within the pharmaceutical industry, providing a comprehensive suite of services encompassing drug discovery, non-clinical development, and safety testing. With a global footprint that extends across the United States, Europe, Canada, the Asia Pacific, and other international markets, the company is recognized for its integrated solutions that support the entire drug development cycle. It operates through three primary segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing), each tailored to meet the varied and complex needs of its clients. Founded in 1947 and headquartered in Wilmington, Massachusetts, Charles River Laboratories is dedicated to aiding its clients in the development of novel therapies and medicines through its vast expertise and comprehensive facilities.
Research Models and Services (RMS): This segment is integral to Charles River Laboratories' operations, producing and selling a wide variety of research rodents, including purpose-bred rats and mice. These are essential tools for researchers across the globe, enabling a myriad of scientific investigations and discoveries. Services offered within this segment also include:
Discovery and Safety Assessment (DSA): A critical segment that supports early-stage drug discovery and safety assessment. The DSA segment delivers:
Manufacturing Solutions (Manufacturing): This segment provides critical support in the quality control and testing of pharmaceuticals and consumer products. It encompasses: